There are 2789 resources available
1034TiP - ARTISTRY-6: Nemvaleukin alfa monotherapy in patients with advanced mucosal and cutaneous melanoma
Presenter: Richard Carvajal
Session: ePoster Display
1035TiP - A phase I/Ib study of MPT-0118 as monotherapy and in combination with pembrolizumab in subjects with advanced or metastatic solid tumors
Presenter: David Sommerhalder
Session: ePoster Display
Resources:
Abstract
1042P - Anti-PD1 (PD1) monotherapy or in combination with ipilimumab (IPI) after BRAF/MEK inhibitors (BRAF/MEKi) in BRAF mutant metastatic melanoma (MM) patients (pts)
Presenter: Ines Pires da Silva
Session: ePoster Display
1043P - NF1 mutations and immune checkpoint inhibitor outcomes in patients with BRAF wildtype melanoma
Presenter: Maysa Vilbert
Session: ePoster Display
1044P - Sequential targeted and immunotherapies in stage IV melanoma
Presenter: Teresa Amaral
Session: ePoster Display
1045P - Comparison between first-line target therapy and immunotherapy in different prognostic categories of BRAF mutant metastatic melanoma patients
Presenter: Riccardo Marconcini
Session: ePoster Display
1046P - First-line anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy in Japanese mucosal melanoma: A retrospective, multicenter study (JMAC study)
Presenter: Yasuhiro Nakamura
Session: ePoster Display
1047P - Efficacy of checkpoint inhibitors (CPIs) in acral melanoma (AM)
Presenter: Prachi Bhave
Session: ePoster Display
1048P - Baseline and post-treatment biomarkers of resistance to anti-PD-1 (aPD1) therapy in acral and mucosal melanoma
Presenter: Jeeyun Lee
Session: ePoster Display
1049P - Clinical models to predict response in mucosal melanoma (MM) patients (pts) treated with anti-PD-1 (PD1) or combined with ipilimumab (PD1+IPI)
Presenter: Florentia Dimitriou
Session: ePoster Display